Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer

2005 ◽  
Vol 206 (2) ◽  
pp. 205-213 ◽  
Author(s):  
VJ Gnanapragasam ◽  
S Darby ◽  
MM Khan ◽  
WG Lock ◽  
CN Robson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Hormone Receptors ◽  
Gonadotropin Releasing Hormone ◽  
Hormone Refractory Prostate Cancer ◽  
Releasing Hormone ◽  
Hormone Refractory

scholarly journals Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions

2020 ◽  
Vol 21 (24) ◽  
pp. 9511
Author(s):  
Fabrizio Fontana ◽  
Monica Marzagalli ◽  
Marina Montagnani Marelli ◽  
Michela Raimondi ◽  
Roberta Moretti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trials ◽  
Hormone Receptors ◽  
Early Stage ◽  
Disease Free Survival ◽  
Gonadotropin Releasing Hormone ◽  
Gnrh Agonists ◽  
Castration Resistant Prostate Cancer ◽  
Releasing Hormone ◽  
Reproductive Axis

Pituitary Gonadotropin-Releasing Hormone receptors (GnRH-R) mediate the activity of the hypothalamic decapeptide GnRH, thus playing a key role in the regulation of the reproductive axis. Early-stage prostate cancer (PCa) is dependent on serum androgen levels, and androgen-deprivation therapy (ADT), based on GnRH agonists and antagonists, represents the standard therapeutic approach for PCa patients. Unfortunately, the tumor often progresses towards the more aggressive castration-resistant prostate cancer (CRPC) stage. GnRH receptors are also expressed in CRPC tissues, where their binding to both GnRH agonists and antagonists is associated with significant antiproliferative/proapoptotic, antimetastatic and antiangiogenic effects, mediated by the Gαi/cAMP signaling cascade. GnRH agonists and antagonists are now considered as an effective therapeutic strategy for CRPC patients with many clinical trials demonstrating that the combined use of these drugs with standard therapies (i.e., docetaxel, enzalutamide, abiraterone) significantly improves disease-free survival. In this context, GnRH-based bioconjugates (cytotoxic drugs covalently linked to a GnRH-based decapeptide) have been recently developed. The rationale of this treatment is that the GnRH peptide selectively binds to its receptors, delivering the cytotoxic drug to CRPC cells while sparing nontumor cells. Some of these compounds have already entered clinical trials.

604: A Phase I Trial of Vaccination of Personalized Peptides for HLA-A2/A24 Positive Patients with Hormone-Refractory Prostate Cancer

2007 ◽  
Vol 177 (4S) ◽  
pp. 202-202
Author(s):  
Hirotsugu Uemura ◽  
Motoyoshi Tanaka ◽  
Shigeya Uejima ◽  
Takafumi Minami ◽  
Kiyohide Fujimoto ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase I ◽  
Phase I Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory
Sign in / Sign up

Export Citation Format

Share Document